Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2551 to 2565 of 8238 results

  1. Upadacitinib for treating giant cell arteritis [ID6299]

    In development Reference number: GID-TA11330 Expected publication date:  21 May 2026

    Technology appraisal guidance
    In development

  2. Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

    In development Reference number: GID-TA11774 Expected publication date:  30 September 2026

    Technology appraisal guidance
    In development

  3. Galcanezumab for migraine [TSID10663]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Belzutifan for treating advanced pheochromocytoma or paraganglioma [TSID12304]

    Awaiting development Reference number: GID-TA11928 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [TSID12303]

    Awaiting development Reference number: GID-TA11929 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [TSID12299]

    Awaiting development Reference number: GID-TA11930 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465]

    Awaiting development Reference number: GID-TA11703 Expected publication date:  04 February 2026

    Technology appraisal guidance
    Awaiting development

  8. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]

    In development Reference number: GID-TA11694 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]

    Awaiting development Reference number: GID-TA11876 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542

    In development Reference number: GID-TA11525 Expected publication date:  10 February 2027

    Technology appraisal guidance
    In development

  12. Xanomeline tartrate–trospium chloride for treating schizophrenia [TSID12311]

    Awaiting development Reference number: GID-TA11925 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Vedolizumab for treating moderately to severely active Crohn's disease in people 2 to 17 years [TSID12312]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Apraglutide for treating short bowel syndrome [ID6533]

    In development Reference number: GID-TA11695 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Secukinumab for treating relapsed polymyalgia rheumatica [ID6599]

    Awaiting development Reference number: GID-TA11806 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development